RE:RE:RE:Christophe said nothing of value during the Q2 callWhen Chrtistophe Degois was asked what the market size would be for the ADC failed / ADC non-tolerant market for the HR+/HER2- metastatic breast cancer market he punted his answer for the next quarter, notwithstanding that he had at least 3 months since he was hired to prepare and give a reasonably informed response, especially since he apparently has ADC BD experience.